<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01224652</url>
  </required_header>
  <id_info>
    <org_study_id>KCSG-ST10-01</org_study_id>
    <nct_id>NCT01224652</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Paclitaxel Versus Irinotecan in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy</brief_title>
  <official_title>A Randomized, Multicenter Phase III Study to Assess the Efficacy of Paclitaxel Versus Irinotecan in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korean Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Korean Cancer Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study is to compare the efficacy of paclitaxel monotherapy
      with irinotecan monotherapy as defined by progression-free survival (PFS), in all patients
      with recurrent and metastatic gastric cancer who progress following first line therapy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>every 8 weeks</time_frame>
    <description>Tumor evaluation using RECIST v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>up to 4 weeks after last administration of chemotherapy</time_frame>
    <description>Number of Participants and toxicity grade accordong to NCI-CTCAE v3.0 as a Measure of Safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">518</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel 70 mg/m2 on Days 1, 8 and 15 of a 28-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>irinotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>irinotecan 150 mg/m2 on Days 1 and 15 of a 28-day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel, 70 mg/m2 will be administered as an intravenous (IV) infusion over 1 hour on Days 1, 8 and 15 of a 28-day cycle</description>
    <arm_group_label>paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>irinotecan 150 mg/m2 will be administered as an intravenous (IV) infusion over 1 hour on Days 1 and 15 of a 28-day cycle</description>
    <arm_group_label>irinotecan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed gastric adenocarcinoma in tissue/cell

          -  Recurrent or metastatic gastric cancer that has progressed following first- line
             therapy

          -  Patients must be ≥18 years of age.

          -  ECOG performance status ≤ 2

          -  At least one lesion (measurable or non-measurable but evaluable) according to RECIST
             criteria

          -  Normal organ and bone marrow function measured within 2 weeks prior to administration
             of study treatment as defined below: Haemoglobin ≥ 9.0 g/dL White blood cells (WBC) ≥
             3000/µL Absolute neutrophil count (ANC) ≥ 1500/µL Platelet count ≥ 100 x 103/µL Total
             bilirubin ≤ 1.5 x upper normal limit (UNL) Creatinine clearance ≥ 60 ml/min or Serum
             creatinine ≤ 1.5 x UNL AST (SGOT)/ALT (SGPT) ≤ 2.5 x UNL unless liver metastases are
             present in which case it must be ≤ 5x UNL

          -  Life expectancy ≥ 12 weeks.

          -  Written informed consent

          -  Provision of informed consent for genetic research (In case of optional genetic
             research)

        Exclusion Criteria:

          -  More than one prior chemotherapy regimen for the treatment of gastric cancer in the
             metastatic or recurrent setting.

          -  Treatment with any investigational product during the last 14 days (or a longer period
             depending on the defined characteristics of the agents used).

          -  Any previous treatment with a taxane, including paclitaxel and docetaxel or
             irinotecan, in the metastatic or recurrent setting.

          -  Patients with second primary cancer, except: adequately treated non- melanoma skin
             cancer, curatively treated in-situ cancer of the cervix, or other solid tumors
             curatively treated with no evidence of disease for ≥5 years.

          -  Patients receiving any systemic chemotherapy, radiotherapy (except for palliative
             reasons), within 2 weeks from the last dose prior to study treatment (or a longer
             period depending on the defined characteristics of the agents used).

          -  Ongoing toxicities (&gt;CTCAE grade 2) caused by previous cancer therapy.

          -  Clinically proven gastric outlet obstruction or CTCAE grade 3 or grade 4 upper GI
             bleeding

          -  Medically uncontrolled, clinically significant heart disease or infection

          -  Patients with symptomatic uncontrolled brain metastases.

          -  Major surgery within 2 weeks of starting study treatment and patients must have
             recovered from any effects of any major surgery.

          -  Women who have pregnancy potential or willing to pregnant. Pregnant and breastfeeding
             women.

          -  Others Poor medical risk due to a serious, uncontrolled medical disorder, non-
             malignant systemic disease or active, uncontrolled infection Any psychiatric disorder
             that prohibits obtaining informed consent and regular follow-up. Inappropriate patient
             for subjects of this study on investigator's judgment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tae-You Kim, M.D., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Korean Cancer Stusy Group stomach Cancer Committee</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tae-You Kim, M.D., Ph.D.</last_name>
    <phone>82-2-2072-3943</phone>
    <email>kimty@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jae Yong Cho, M.D., Ph.D.</last_name>
    <phone>82-2-2019-4363</phone>
    <email>chojy@yuhs.ac</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yonsei University Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>135-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jae Yong Cho, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tae-You Kim, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2010</study_first_submitted>
  <study_first_submitted_qc>October 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2010</study_first_posted>
  <last_update_submitted>October 19, 2010</last_update_submitted>
  <last_update_submitted_qc>October 19, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2010</last_update_posted>
  <responsible_party>
    <name_title>Tae-You Kim, Chairperson of Stomach Cancer Committee</name_title>
    <organization>Korean Cancer Study Group</organization>
  </responsible_party>
  <keyword>gastric cancer</keyword>
  <keyword>paclitaxel</keyword>
  <keyword>irinotecan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

